Viatris Targets 5%-6% Revenue Growth and $3B Free Cash Flow by 2030
Viatris projects 5%-6% total revenue CAGR, 7%-8% adjusted EBITDA growth and 9%-10% adjusted EPS CAGR through 2030, targeting over $3 billion in free cash flow by 2030. It plans to deploy over $11 billion in cash for near-term launches of fast-acting meloxicam, a low-dose estrogen patch, pitolisant and Effexor for GAD.
1. Strategic Vision and Long-Term Targets
Viatris aims for 5%–6% total revenue CAGR, 7%–8% adjusted EBITDA CAGR and 9%–10% adjusted EPS CAGR from 2025 to 2030, targeting over $3 billion in free cash flow by 2030 under a combined plan that includes both base case and additional growth drivers.
2. Near-Term Product Launches
The company anticipates launching fast-acting meloxicam and a low-dose estrogen weekly patch in the U.S., alongside pitolisant and Effexor for generalized anxiety disorder in Japan, to bolster its higher-margin generics and value-added medicines portfolio.
3. Cash Flow Generation and Capital Allocation
Viatris expects to have more than $11 billion in cash available through 2030, with up to half allocated to disciplined, accretive business development, following $650 million in identified cost savings and $250 million earmarked for reinvestment.
4. Pipeline and Portfolio Evolution
Beyond its base business, the pipeline features potential blockbusters selatogrel and cenerimod, while ongoing portfolio simplification and an enterprise-wide strategic review support durable margin expansion and shareholder returns.